Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Corporate Update (April 2025)
26 slides from Optiscan Imaging's corporate update, Apr 10, 2025
Slide 1: The new standard in digital pathology and precision surgery
The new standard in digital pathology and precision surgery. Optiscan Imaging Ltd. (ASX:OIL) Optiscan Site Tour – Analyst Presentation 10 April 2025 This presentation has been approved by the Board of Optiscan for market release. Commercial in Confidence
Slide 2: Notice
Notice This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) 10 April 2025, and approved for market release by the Board of Optiscan. The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all
Slide 3: Optiscan at a Glance
Optiscan at a Glance A global medical technology company leading the transformation of digital pathology and precision surgery ASX: OIL Melbourne $110m Patent Proven Validated Team 2,350 m2 QMS Minnesota 1997 Headquarters Market Cap Protected Technology Products Agile Office & Plant Certification Co
Slide 4: Best in Class - Unparallelled Precision
Best in Class - Unparallelled Precision Technology Image – Mouse Ilium Comparison Single fibre Whole imaging plane is scanned No blank spots, all critical clinical information displayed No image processing, stitching or mosaicking required Sub-micron optical resolution with optimal image s
Slide 5: Proven + Validated Technology
Proven + Validated Technology Tissue Agnostic with Excellent Correlation to Conventional Pathology Commercial in Confidence
Slide 6: Live Microscopic Imaging
Live Microscopic Imaging Commercial in Confidence
Slide 7: The Optiscan Opportunity
The Optiscan Opportunity Artificial Intelligence $20.9 billion Clinical Life $10 trillion Sciences $144 billion Veterinary $46.51 billion Surgery $45.4 bn $US from referenced sources available on request. Commercial in Confidence
Slide 8: Strategic Transformation
Strategic Transformation • Governance • Compliance • Operations • Manufacturing • Clinical • Regulatory • Commercial • Legal OEM to PLM Optiscan Imaging Portfolio Strategic Diversification Partnerships • Hardware • Mayo Clinic • Software • Uni Mainz • Medical • Uni Minnesota • Veterinary • Uni Monas
Slide 9: Progress to date
Progress to date o Sales & marketing appointments in AU o InVue® reveal (Surgery) Artificial Intelligence and US o Defined regulatory pathway for InVue® o Outsourced business development in EU Q3FY25 o Renewed distributor agreements in APAC o InForm® reveal (Pathology) o ViewnVivo® expanding sales p
Slide 10: Positioned for Growth
Positioned for Growth Phase 1: Core foundation Phase 2: Strategic transformation Phase 3: Strategic growth o Strategic focus o Digital health solutions o Develop core platform leader and initial product o Optimised operations offering o Full suite of digital health o Investment in growth products o
Slide 11: Growing Footprint & Sales Pipeline
Growing Footprint & Sales Pipeline European Union Business Development Sales & Marketing Beijing, China Distribution Sinsi Technologies Ltd Rochester MN, United States Regional Office Clinical & Regulatory Business Development Sales & Marketing Shanghai, China Distribution Biotimes Technology Ltd Me
Slide 12: FY24 Financial Highlights
FY24 Financial Highlights Strong capital position and increased income. Cash and Term Deposits $16.7m capital raised to advance multiple R&D projects $M 12 Balance sheet in FY24 remained strong with a cash and term deposit 10 balance of $11.2m 8 6 Balance as of Feb25 remains strong at $7.1m 4 2
Slide 13: FY25 Market Update
FY25 Market Update Projected increased revenue from sales and other income. Revenue and Other Income FY25 Total Income (Revenue & Other Income) projected to increase up to 20%, approximately $4.2m from FY24 Revenue Other Income Revenue from sale of products $M 5 FY25 revenue from ViewnVivo® sales
Slide 14: Diversified Hardware & Software Portfolio
Diversified Hardware & Software Portfolio Clinical Device Family Vision + Full Suite of Digital Health Assets Live Streaming Telepathology Software & AI Based Software as a Biopsy Channel Compatible Integration with Robotics Image-guided Remote Diagnostics Medical Device Devices Systems Molecular Su
Slide 15: Product Family Vision Brought to Life
Product Family Vision Brought to Life Life Sciences Oral Surgical Pathology Commercial in Confidence
Slide 16: InVue
Optiscan
Slide 17: InForm
InForm Commercial in Confidence
Slide 18: InForm
InForm Commercial in Confidence
Slide 19: Breast Cancer Imaging
Breast Cancer Imaging Commercial in Confidence
Slide 20: Breast Imaging
Breast Imaging Normal Breast Tissue Invasive Breast Carcinoma H&E CLE H&E CLE Commercial in Confidence
Slide 21: Telepathology
Telepathology • Cloud hosted webapp utilizing microservice based architecture for device management, security, storage, and data processing. • Custom pathologist web portal interface for data access, real-time telepathology support, historical data review, and reporting. • Video streaming utilizing
Slide 22: AI/ML
AI/ML • Machine learning and image processing pipeline running directly on the device to process images in real-time • Pipeline broken down into multiple ML and traditional computer vision algorithms for: Image pre-processing, filtering, and masking Nuclei extraction Cell boundary segmentation
Slide 23: Product Pipeline - By Development Stage
Product Pipeline - By Development Stage Application Stage Collaborators Veterinary IDEATION PROTOTYPING PRECLINICAL CLINICAL 2025-2026 REGULATORY 2026 LAUNCH MONITORING Surgical CLINICAL REGULATORY IDEATION PROTOTYPING PRECLINICAL LAUNCH MONITORING 2025-2026 2027 Pathology IDEATION PROTOTYPING PRECL
Slide 24: Optiscan Investment Opportunity
Optiscan Investment Opportunity Value Proposition Revolutionary Patent- Versatility of Platform & Diversified Hardware & Limitless Growth Potential Protected Technology Global Applications Software Offerings Market Differentiators & Investment Thesis Competitive High Barrier To Entry Revenue + Marke
Slide 25: Contact Us
Contact Us Dr Camile Farah MBA, PhD, MAICD, FAIM, FLWA CEO & Managing Director Optiscan Imaging Ltd (ASX:OIL) ceo@optiscan.com /company/Optiscan www.optiscan.com Commercial in Confidence
Slide 26: Optiscan
Optiscan”